Wednesday 14 November 2018 | ShareProphets: The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares
Tom Winnifrith Bearcast: I agree with everyone on one matter & with in house Bulletin Board loon Wildes on another
Maistro – fundraising at a massive discount, despite in September arguing “significant progress” & “looking forward with confidence”!
Writing on Akers Biosciences (AKR & NASDAQ - AKER) last month - “decided to withdraw” an initial FDA application… & worse, I concluded to run for the hills from this stock. Now, the shares are slumping again – this time on a “Notification of Class Action” announcement. Uh oh…
A slump in shares in Akers Biosciences (AKR & NASDAQ - AKER) was noted in Bearcast yesterday, what’s the detail?...
The ideal scenario as far as charting a stock or market is concerned is that you do not necessarily have to do the dirty work in terms of trying to work out what will happen next – the price action does it for you.
Interesting "players" in the small cap world are buying into AIM listed Akers Biosciences (AKR) and we suggest following suit at 2.375p with an initial target of 4.5p. Here’s why.
Search ShareProphets |
Recent Comments |